Soluble CTLA4 Mutant Molecule that binds to CD80 and / or CD86 Molecule that encodes a Nucleic Acid, Vector and vector system that includes the latter, host cell that possesses a Mutant Protein and Method for producing this Protein Molecule, the use of Mutant to prepare a Medic

摘要

A Mutant CTLA4 Molecule binds to CD80 and CD86 and / or, comprising an extracellular domain of CTLA4 extracellular domain, so that (a) an alanine at position + 29 is replaced with an amino acid selected from the group consisting of Leucine, tyrosine, tryptophan and threonine And (b) a Leucine at position + 104 is located with a glutamic acid.This Mutant Molecule CTLA4 also comprises an Amino Acid Sequence that Alters the solubility, Affinity or the Valencia of the Mutant soluble CTLA4 Molecule, where the Amino Acid Sequence can include a human immunoglobulin Constant region, and can understand A sequence of amino acids that allow the secretion of soluble CTLA4 Mutant Molecule.The Amino Acid Sequence may include a Signal peptide oncostatin M. Nucleic Acid Molecule comprising a Nucleotide sequence encoding an Amino Acid Sequence corresponding to the Mutant soluble CTLA4 Molecule.Vector comprising a Nucleotide sequence of the Nucleic Acid Molecule and host vector system that includes the Vector in a host Cell, which can be a eukaryotic cell.Method for producing a Protein soluble CTLA4 Mutant host vector comprises the development of the system to produce the Mutant Protein of CTLA4 in the host Cell, and recover the Protein thus produced, and Method for regulating the interaction of a T cell with a cell po Positive to CD80 and / or CD86.Use of Mutant CTLA4 Molecule to prepare a Medicine pharmacist and Pharmaceutical medicine for treating a disease of the immune system, which comprises a pharmaceutically acceptable Carrier and the soluble CTLA4 Mutant Molecule.